Effect of yohimbine-trazodone on psychogenic impotence: a randomized, double-blind, placebo-controlled study.
OBJECTIVE
The aim of this study was to determine the effectiveness and safety of yohimbine and trazodone used together for the treatment of pure psychogenic impotence.


METHODS
Sixty-three patients who had psychogenic impotence diagnosed on the basis of sexual history, results of physical examination, laboratory analysis, polysomnographic recording of nocturnal erections, and dynamic color Doppler sonography of the cavernosal arteries were entered into a randomized, double-blind, placebo-controlled, partial crossover study comparing placebo with yohimbine (15 mg per day orally) and trazodone (50 mg per day orally) used together. Treatment consisted of two 8-week courses. Patients who initially received placebo for 8 weeks were then switched to the 2-drug combination for 8 weeks. Erectile function, ejaculation, interest in sex, and sexual thoughts were investigated at the end of drug treatment and at 3- and 6-month follow-up. For statistical analysis chi-square, McNemar, and Student's t test for unpaired data were used.


RESULTS
Fifty-five patients (87%) completed the whole treatment schedule. Positive clinical results (complete and partial responses) were obtained in 39 (71%) patients at the end of the drug treatment phase. These results were significantly better than those obtained with placebo (p < 0.01). Positive results were maintained in 32 (58%) and 31 (56%) patients at 3- and 6-month follow-up, respectively. Minor drug-related adverse effects occurred in 6 (11%) of the patients in the yohimbine-trazodone group and in 2 (4%) in the placebo group.


CONCLUSIONS
The combination of yohimbine and trazodone is a safe and effective first-line treatment for psychogenic impotence.
Montorsi
F
F
Institute of Human Anatomy, Scientific Institute H. San Raffaele, Milan, Italy.
Strambi
L F
LF
Guazzoni
G
G
Galli
L
L
Barbieri
L
L
Rigatti
P
P
Pizzini
G
G
Miani
A
A
D000284:Administration, Oral; D000328:Adult; D018592:Cross-Over Studies; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D007172:Erectile Dysfunction / Q000188:drug therapy* / Q000523:psychology; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D011602:Psychophysiologic Disorders / Q000188:drug therapy*; D013997:Time Factors; D014196:Trazodone / Q000627:therapeutic use*; D015016:Yohimbine / Q000627:therapeutic use*
D015016:Yohimbine; D014196:Trazodone